While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

This is a common occurrence in patients taking biologic therapies for psoriasis, as over time many start producing anti-drug antibodies (ADA), reducing the effectiveness of their existing treatment.

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

Psoriasis is one of the most common chronic ... a study shows that it is possible to restore the function of certain anti-inflammatory immune cells in a targeted manner. The results pave the ...